Aytemiz Gürgey

Aytemiz Gürgey

Auto-generated profile, based on publicly available information

Aytemiz Gürgey

Hacettepe University, Faculty of Medicine, Department of Pediatrics, Institute of Child Health and Section of Pediatric Hematology, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2003 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
GBGunay Balta
Gunay Balta
NYNazmiye Yuksek
Nazmiye Yuksek
EUEmel Uzunoglu
Emel Uzunoglu
UEUlya Ertem
Ulya Ertem
GHGonul Hicsonmez
Gonul Hicsonmez
AGAytemiz Gurgey
Aytemiz Gurgey

1 September 2005 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
AGAytemiz Gürgey
Aytemiz Gürgey
SASelin Aytac
Selin Aytac
GKGuler Kanra
Guler Kanra
GSGulten Secmeer
Gulten Secmeer
MCMehmet Ceyhan
Mehmet Ceyhan
CACigdem Altay
Cigdem Altay
Purpura fulminans (PF) is a severe disorder of acute onset with high morbidity and mortality. In children, this rapidly progressive illness is usually associated with severe bacterial or viral infections. However, some other conditions may participate in the development of PF. Our objective was to investigate the underlying and associated disorders and the outcomes of the disease in 16 children, 7 males and 9 females ranging in age from 3.5 months to 12 years (median age, 2 years). Thirteen of the 16 children (81%) were 4 years of age or younger. The remaining 3 patients were 9, 10, and 12 years of age. Among these 13 infants and small children, 7 (43%) had infection, 2 infants had congenital cardiac disorders necessitating minor or major surgical intervention, and 1 infant and 3 children had different miscellaneous disorders. The factor V G1691A mutation was present in six of the 13 small children (46%). None of the 3 older children carried the mutation. Six (37.5%) of the 16 patients had protein C deficiencies, and 9 (56%) had protein S deficiencies. These deficiencies, except one for protein S, were acquired. Ten patients except two who were diagnosed at this center were treated with fresh frozen plasma. They were also given heparin. Nine (69%) of the 13 children 4 years of age or younger and one of the older children (33%) required amputation. Five of the six patients (83%) who had factor V G1691A mutation, and who also exhibited severe infection, required amputation. This study suggests that an age of 4 years or less is a risk factor for the development of PF during severe infections, especially in the presence of factor V G1691A mutation and congenital heart disease, necessitating major or minor surgical interventions. This study also shows that the amputation rate in 10 patients, after excluding the patients who had been referred to our center after development of sequelae, was 60%. The survival rate among these 10 patients may indicate that, with the treatment protocol, PF need not be regarded as a lethal disease any more. It is also suggested that effective immunization programs and better health care have probably resulted in some changes in the etiological profile of PF. Am. J. Hematol. 80:20–25, 2005.

26 February 2005 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
SÜSelma Ünal
Selma Ünal
AVAli Varan
Ali Varan
BYBilgehan Yalçın
Bilgehan Yalçın
MBMünevver Büyükpamukçu
Münevver Büyükpamukçu
AGAytemiz Gürgey
Aytemiz Gürgey

1 December 2005 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
AGAytemiz Gurgey
Aytemiz Gurgey
GSGulten Secmeer
Gulten Secmeer
BTBetul Tavil
Betul Tavil
MCMehmet Ceyhan
Mehmet Ceyhan
BKBaris Kuskonmaz
Baris Kuskonmaz
FGFatma Gumruk
Fatma Gumruk
Between January 1998 and January 2005, a total of 18 children 2 weeks–72 months of age were diagnosed as having secondary hemophagocytic lymphohistiocytosis. The frequency of secondary hemophagocytic lymphohistiocytosis among total hospitalized patients during this period was 0.05% (18 of 34,250). Of the 18 patients, 8 (44.5%) had bacterial infections; cytomegalovirus and Epstein-Barr virus infections were present in 5 (28%) and 1 (5.5%), patient, respectively. Leishmaniasis was diagnosed in 2 patients (11%), and herpes simplex virus was diagnosed in 2 patients (11%). Six patients died during treatment, and 1 patient was lost to follow-up. The survival rate was 61%.

15 March 2008 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
YBYusuf Bayraktar
Yusuf Bayraktar
OHOzgur Harmanci
Ozgur Harmanci
YBYahya Büyükasik
Yahya Büyükasik
ASAli Ibrahim Shorbagi
Ali Ibrahim Shorbagi
ASAysegul Hasegeli Sungur
Aysegul Hasegeli Sungur
FBFerhun Balkanci
Ferhun Balkanci

1 February 2003 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
AGAytemiz Gurgey
Aytemiz Gurgey
GBGunay Balta
Gunay Balta
ABAyse Boyvat
Ayse Boyvat
Behcet's disease is a chronic systemic vasculitis with particular systemic features including thrombotic events. The present study was designed to analyse the role of the factor V Leiden and the prothrombin G20210A mutations and plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk of patients with Behcet's disease. A total of 50 unrelated patients with Behcet's disease (34 male, 16 female) were the subjects of the study. Twenty-seven of 50 patients with a history of thrombosis comprised group 1, and 23 patients with no thrombosis comprised group 2. In group 1, nine of the 27 patients (33%) were found to have the factor V Leiden mutation (7.1% in healthy population), and the 4G/4G genotype was found in 23% of the patients (26% in control). No patient had the prothrombin G20210A mutation (2.2% in healthy control). In group 2, two patients (9%) had the factor V Leiden and one patient (4%) had the prothrombin G20210A mutations. The 4G/4G polymorphism was found in 30.5% of the patients. The differences in the frequencies of factor V Leiden mutation between group 1 and group 2 (odds ratio, 5.3; 95% confidence interval, 1.0–27.5) and between group 1 and the healthy population were statistically significant (P< 0.05). No statistically significant association was found for the prothrombin G20210A mutation and the 4G/5G genotype between the two groups or between each group and the healthy population, indicating that the prothrombin G20210A mutation and the 4G/4G polymorphism do not play a role in the development of thrombosis in Behcet's disease. These data suggested that the factor V Leiden mutation might be a risk factor for the development of thrombosis in Behcet's disease patients.